This post was originally published on this site T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total funding includes $15 million from an investor, in addition to a $9 million award from the National Institute…
About Alzheimer’s Disease
Walking into a room and forgetting why you went into the room is normal. Walking into a room and forgetting what room you are in is not normal. Alzheimer’s disease is the most common form of dementia and affects one in ten people over the age of 65. Unfortunately, the exact cause of Alzheimer’s disease is not fully understood however leading scientific experts in the field attribute the illness to the irreversible and progressive generalized degeneration of the brain. Alzheimer’s disease goes well beyond the forgetfulness that may accompany aging, and typically first signs include difficulty remembering current information or performing new tasks. Ongoing hallmark symptoms include impaired memory function, difficulty performing everyday tasks, and neurobehavioral abnormalities. Currently, there is no known cure for Alzheimer’s disease, and multi-disciplinary treatment focuses on symptom management and limiting progression.
Conditions
Alzheimer’s News
Alzheimer’s Awareness Month in US Focuses on Caregivers, Resources and Education
This post was originally published on this site Efforts are underway this month to focus attention on Alzheimer’s (AD), a disease that, along with other forms of dementia, affects some 44 million people globally and is rapidly growing in prevalence. During November in the U.S., Alzheimer’s Awareness Month observances include online tributes to caregivers, listings of…
Seaweed-based Therapy Approved in China for Mild to Moderate Alzheimer’s, 1st New Treatment in 16 Years
This post was originally published on this site Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in China to treat mild to moderate Alzheimer’s disease (AD), making it the first new disease therapy approved anywhere since Allergan’s Namenda (memantine) in late 2003. The decision was…
High-salt Diet can Cause Dementia by Promoting Accumulation of Tau Plaques, Mouse Study Says
This post was originally published on this site A diet that is high in salt can cause dementia in mice by promoting a buildup of plaques of the protein tau, which is also associated with Alzheimer’s disease, a new study shows. The study, titled “Dietary salt promotes cognitive impairment through tau phosphorylation,” was published in Nature.…
Tips for Navigating Hospital Stays for Those with Alzheimer’s
This post was originally published on this site Of the 5.8 million people in the United States living with Alzheimer’s disease, 5.6 million are age 65 or older. According to a 2009-2010 National Hospital Ambulatory Medical Care Survey, the same demographic accounted for 15% of emergency room visits during that period. ER visits and hospital…
INmune Bio’s XPro1595 May Help Lower Neuroinflammation Triggered by High Fat and Sugar Diet, Mouse Study Suggests
This post was originally published on this site Treatment with INmune Bio‘s lead candidate XPro1595 can help decrease neuroinflammation and amyloid beta accumulation triggered by a diet high in sugar and fats, according to results from a mouse model of Alzheimer’s disease (AD). Malú Tansey, PhD, professor of neuroscience and director of the Center for…
Dementia Phone Service Provider teleCalm Wins $100K Prize for Start-up Development
This post was originally published on this site Landline-style phone service provider teleCalm will use a $100,000 award to advance its new phone service for dementia patients, which helps keep people with Alzheimer’s and related conditions safely connected with family and friends. The Diamond Award was presented by the Austin, Texas offices of MassChallenge, a U.S.-based…
New Blood Test May Help Detect Beta-Amyloid Plaques in People at Risk of Alzheimer’s, Study Shows
This post was originally published on this site Scientists have developed a simple blood test that may help clinicians identify whether a person has accumulations of abnormal amyloid protein deposits in the brain — an event linked to an Alzheimer’s diagnosis. This new laboratory test may represent an alternate diagnostic tool to other expensive brain…
Inaugural Rainwater Prize Winners Focus on Alzheimer’s and Other Brain Research
This post was originally published on this site An eminent Alzheimer’s disease (AD) scientist, Michel Goedert, and an early career genomic engineering investigator, Patrick Hsu, are inaugural winners of the Rainwater Prize Program that acknowledges leading work in brain research. Such work includes groundbreaking efforts to advance new treatments for neurodegenerative disorders, including Alzheimer’s, that are associated with tau protein accumulation…
Early Diagnosis Is Worth the Risk of Offending a Loved One
This post was originally published on this site Sadly, millions of people in the U.S. live with Alzheimer’s disease. Even sadder is that fewer than half of Alzheimer’s patients or their caregivers report being told of the diagnosis by a healthcare provider. An Alzheimer’s Association report from 2015 indicated that only 45 percent of people…
CareBand Tracking Bracelet Wins NIH Award, May Detect Agitation in Alzheimer’s, Related Dementias
This post was originally published on this site CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the National Institutes of Health (NIH) Phase 1 Small Business Innovation Research (SBIR) Award to test whether it may help detect and predict agitation in patients with Alzheimer’s disease…
Biogen to Seek Approval of Aducanumab for Early Alzheimer’s Based on New Analysis of Trials
This post was originally published on this site Biogen is planning to seek approval for aducanumab, an injectable treatment under investigation for patients with early Alzheimer’s disease, following a new analysis of Phase 3 studies supporting meaningful benefits for patients’ cognition and daily life abilities. After meeting with the U.S. Food and Drug Administration (FDA),…